- Home
- ROOT vs DNLI Comparison
ROOT vs DNLI Comparison
Compare ROOT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- DNLI
- Stock Information
- Founded
- ROOT 2015
- DNLI 2013
- Country
- ROOT United States
- DNLI United States
- Employees
- ROOT N/A
- DNLI N/A
- Industry
- ROOT Property-Casualty Insurers
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ROOT Finance
- DNLI Health Care
- Exchange
- ROOT Nasdaq
- DNLI Nasdaq
- Market Cap
- ROOT 2.3B
- DNLI 2.1B
- IPO Year
- ROOT 2020
- DNLI 2017
- Fundamental
- Price
- ROOT $124.70
- DNLI $14.69
- Analyst Decision
- ROOT Buy
- DNLI Strong Buy
- Analyst Count
- ROOT 6
- DNLI 15
- Target Price
- ROOT $134.80
- DNLI $33.85
- AVG Volume (30 Days)
- ROOT 448.2K
- DNLI 1.6M
- Earning Date
- ROOT 08-06-2025
- DNLI 07-31-2025
- Dividend Yield
- ROOT N/A
- DNLI N/A
- EPS Growth
- ROOT N/A
- DNLI N/A
- EPS
- ROOT 3.16
- DNLI N/A
- Revenue
- ROOT $1,271,000,000.00
- DNLI N/A
- Revenue This Year
- ROOT $22.06
- DNLI N/A
- Revenue Next Year
- ROOT $10.86
- DNLI $335.74
- P/E Ratio
- ROOT $39.46
- DNLI N/A
- Revenue Growth
- ROOT 98.66
- DNLI N/A
- 52 Week Low
- ROOT $34.04
- DNLI $10.57
- 52 Week High
- ROOT $181.14
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- ROOT 40.50
- DNLI 54.49
- Support Level
- ROOT $122.24
- DNLI $13.41
- Resistance Level
- ROOT $130.33
- DNLI $14.66
- Average True Range (ATR)
- ROOT 7.74
- DNLI 0.66
- MACD
- ROOT -1.68
- DNLI 0.04
- Stochastic Oscillator
- ROOT 9.87
- DNLI 80.50
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.